Yaniv Heled
Professor of Law Center for Entertainment, Sports & Intellectual Property Law, Center for Law, Health & Society- Education
J.S.D., Columbia University School of Law
LL.M., Columbia University School of Law
LL.B. and undergraduate diploma in biology, magna cum laude, Tel Aviv University
- Specializations
Family Law
Genetics and the Law
Intellectual Property
Law & Psychology
Law & Technology
Pharmaceutical Regulation
- Biography
Yaniv Heled is a national expert on the legal and ethical aspects of biomedical technologies. He has published over 20 academic articles and book chapters on the regulation of pharmaceutical markets, stem cell research, human reproductive tissue, and genetic sequencing and testing, among others. Most recently, Professor Heled co-authored “A Theory of Genetic Dimensions in the Law,” which presents an innovative framework for assisting judges and policymakers in addressing complex legal issues involving genetic science and technology.
Professor Heled’s current research projects examine the legal treatment of a novel statistical tool for assessing genetic risk—polygenic risk scores—in the context of human reproduction, including how judges and policymakers should approach issues involving this new technology. In another project, Professor Heled and co-authors examine the use of non-collegial and aggressive language in Supreme Court opinions and are developing an AI tool for identifying and quantifying such language.
In addition to his wide-ranging scholarship, Professor Heled is active in various policymaking efforts in the areas of pharmaceutical regulation, access to medicines, and regulation of reproductive technologies. He has authored and joined numerous amicus briefs, administrative agency comments, and white papers on matters related to these areas, and he regularly provides advice to not-for-profits and policymakers.
Professor Heled is on the faculty of Georgia State University’s Center for Law, Health & Society, which runs the top-ranked health law program in the United States and of the Georgia State University Center for Intellectual Property Law, of which he was the inaugural director. He teaches Patent Law, Family Law, Legislation & Regulation, Biotechnology Law, and Mental Health Law.
Prior to joining Georgia State Law, Professor Heled practiced intellectual property law with Goodwin Procter LLP in New York. He earned a J.S.D. from Columbia University School of Law. His doctoral dissertation focused on the regulation of novel biomedical technologies. In addition, Professor Heled holds an LL.M. from Columbia, where he was a Harlan Fiske Stone Scholar, and an LL.B. and undergraduate Diploma in Biology, magna cum laude, from Tel Aviv University.
- Publications
Book Chapters
Yaniv Heled & Liza Vertinsky, Genetic Paparazzi, in Consumer Genetic Technologies: Ethical and Legal Considerations (I. Glenn Cohen, et al., eds. 2021).
Yaniv Heled, Biologics, Biosimilars and Other Idiosyncrasies, in Contemporary Issues in Pharmaceutical Patent Law 47 (Bryan Mercurio & Daria Kim, eds. 2017).
Articles
Stacie P. Kershner, Erin C. Fuse Brown, Leslie E. Wolf, Paul A. Lombardo, & Yaniv Heled, Introduction: Defining Health Law for the Future: A Tribute to Charity Scott, 52 J.L. Med. & Ethics 216 (2024).
Yaniv Heled, et al., A Theory of Genetic Dimensions in the Law, 99 Ind. L.J. 1341 (2024).
Yaniv Heled, et al., Righting a Reproductive Wrong: A Statutory Tort Solution to Misrepresentation by Reproductive Tissue Providers, 60 Hous. L. Rev. 1 (2022).
Yaniv Heled et al., The Need for the Tort Law Necessity Defense in Intellectual Property Law, 2021 U. Chi. Legal F. 127 (2021)
Yaniv Heled & Liza Vertinsky, Genetic Paparazzi: Beyond Genetic Privacy, 82 Ohio St. L.J. 409 (2021).
Yaniv Heled et. al., Regulatory Reactivity: FDA and the Response to Covid-19, 76 Food & Drug L.J. 318 (2021)
Yaniv Heled, Timothy Lytton & Liza Vertinsky, A Wrong Without a Remedy: Leaving Parents and
Children With a Hollow Victory in Lawsuits Against Unscrupulous Sperm Banks, 96 Chi.-Kent L. Rev. 115 (2021)
Yaniv Heled, The Case for Disclosure of Biologics Manufacturing Information, 47 J. L. Med. & Ethics 54 (2019).
Yaniv Heled, Follow-On Biologics Are Set Up to Fail, 2018 U. Ill. L. Rev. Online 113.
Yaniv Heled, Regulatory Competitive Shelters, 76 Ohio St. L.J. 299 (2015).
Yaniv Heled, On Patenting Human Organisms or How the Abortion Wars Feed Into the Ownership Fallacy, 36 Cardozo L. Rev. 241 (2014).
Shine Tu, et al., Response to 'Pervasive Sequence Patents Cover the Entire Human Genome', 6 Genome Med. 14 (2014).
Yaniv Heled, Why Primary Patents Covering Biologics Should Be Unenforceable Against Generic Applicants Under the Biologics Price Competition and Innovation Act, 21 Annals Health L. 211 (2012).
Frederick H. Rein, Scott A. Warren, & Yaniv Heled, Healthcare Reform Creates Pathway for Biosimilar Biologics, ipFrontline (Apr. 9, 2010).
Yaniv Heled, The Regulation of Genetic Aspects of Donated Reproductive Tissue - The Need for Federal Regulation, 11 Colum. Sci. & Tech. L. Rev. 243 (2010).
Yaniv Heled, On Presidents, Agencies, and the Stem Cells Between Them: A Legal Analysis of President Bush's and the Federal Government’s Policy on the Funding of Research Involving Human Embryonic Stem Cells, 60 Admin. L. Rev. 65 (2008).
Popular Press
Yaniv Heled, Alter Rules of Liability, Atlanta J.-Const., Oct. 7, 2014, at A12.
Yaniv Heled, Why Deny Parents New Technology?, Haaretz, May 24, 2005, at B2.